ReNeuron Group plc (RNUGF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ReNeuron Group plc (RNUGF) trades at $0.0011 with AI Score 57/100 (Grade B). ReNeuron Group plc is a UK-based biotechnology company focused on developing cell-based therapies for areas of significant unmet medical need. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for RNUGF: RNUGF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RNUGF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
RNUGF: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
ReNeuron Group plc (RNUGF) Healthcare & Pipeline Overview
ReNeuron Group plc, a UK-based biotechnology firm, specializes in cell-based therapies, including its CTX stem cell therapy for stroke disability and human retinal progenitor cell therapy for retinitis pigmentosa. Trading on the OTC market, the company focuses on innovative treatments within the regenerative medicine landscape.
What Is the Investment Thesis for RNUGF?
ReNeuron Group plc presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on cell-based therapies for stroke disability and retinitis pigmentosa addresses significant unmet medical needs. Successful completion of Phase 2 trials for the hRPC therapy could be a major catalyst, driving significant value. However, the company's negative ROE of -106.8% and negative free cash flow highlight the financial challenges inherent in biotechnology development. The company's reliance on the OTC market also introduces liquidity and regulatory risks. Investors should carefully weigh the potential for breakthrough therapies against the financial and operational uncertainties.
Based on FMP financials and quantitative analysis
RNUGF Key Highlights
ReNeuron is developing CTX stem cell therapy for stroke disability, a significant unmet medical need.
- The company's human retinal progenitor cell therapy is in Phase 2 clinical trials for retinitis pigmentosa.
- ReNeuron is exploring CTX-derived exosomes for therapeutic applications in pre-clinical studies.
- The company has a collaboration agreement with University College London for anti-cancer cell therapies.
- ReNeuron licenses ReNcell products, providing research tools for cell biology and neuroscience.
Who Are RNUGF's Competitors?
RNUGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MESO Mesoblast Limited | $17.49 | +2.10% | $2.27B | 65 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RNUGF's Key Strengths?
Proprietary cell-based therapy technologies.
- Focus on unmet medical needs.
- Collaboration with University College London.
- Pipeline of product candidates in various stages of development.
What Are RNUGF's Weaknesses?
Negative ROE and free cash flow.
- Reliance on the OTC market.
- Limited financial resources.
- High risk of clinical trial failure.
What Could Drive RNUGF Stock Higher?
RNUGF catalyst: Publication of Phase 2 clinical trial results for human retinal progenitor cell therapy for retinitis pigmentosa.
- Initiation of clinical trials for CTX-derived exosomes.
- Advancement of CTX stem cell therapy for stroke disability through clinical trials.
- Expansion of ReNcell product licensing.
- Progress in collaboration with University College London on anti-cancer cell therapies.
What Are the Key Risks for RNUGF?
Financial-distress signal — its Altman Z-Score of -38.75 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-72.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure of clinical trials for key product candidates.
- Regulatory delays or rejection of product approvals.
- Competition from established pharmaceutical companies.
- Limited financial resources and need for additional funding.
- Risks associated with trading on the OTC market.
What Are the Growth Opportunities for RNUGF?
- Growth opportunity 1: Successful completion of Phase 2 clinical trials for the human retinal progenitor cell (hRPC) therapy targeting retinitis pigmentosa could unlock a significant market opportunity. Retinitis pigmentosa affects approximately 1 in 4,000 people worldwide, creating a substantial patient population. Positive trial results could lead to accelerated regulatory approval and commercialization, driving revenue growth. The timeline for Phase 2 completion is estimated within the next 12-18 months, with potential for market entry within 3-5 years.
- Growth opportunity 2: Advancing the CTX stem cell therapy for stroke disability through clinical trials represents a major growth driver. Stroke is a leading cause of long-term disability, and there is a significant need for effective treatments to restore neurological function. Positive clinical trial outcomes could position ReNeuron as a leader in stroke rehabilitation, capturing a substantial share of the market. The timeline for further clinical development and potential commercialization is estimated at 3-5 years.
- Growth opportunity 3: The development of CTX-derived exosomes for therapeutic applications offers a novel growth avenue. Exosomes have the potential to deliver therapeutic molecules to target cells, offering a versatile platform for treating various diseases. Pre-clinical studies are ongoing, with potential for clinical trials within the next 2-3 years. Successful development could lead to partnerships with pharmaceutical companies and expansion into new therapeutic areas.
- Growth opportunity 4: Expanding the licensing of ReNcell products provides a steady revenue stream and supports the company's research and development efforts. ReNcell products are used by researchers in cell biology and neuroscience, creating a diverse customer base. Increasing the product portfolio and expanding into new geographic markets could drive further growth in this segment. The timeline for expansion is ongoing, with continuous efforts to enhance product offerings and reach new customers.
- Growth opportunity 5: Collaborating with University College London to develop immune cell therapies for cancer represents a strategic growth opportunity. Cancer is a major global health challenge, and there is a significant need for innovative therapies. Successful development of immune cell therapies could position ReNeuron as a player in the oncology market, attracting partnerships and investment. The timeline for clinical development and potential commercialization is estimated at 5-7 years.
What Threats Does RNUGF Face?
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Technological advancements that render current therapies obsolete.
- Economic downturn affecting healthcare spending.
What Are RNUGF's Competitive Advantages?
- Proprietary cell-based therapy technologies.
- Patents protecting key product candidates.
- Clinical trial data demonstrating safety and efficacy.
- Expertise in regenerative medicine and cell therapy.
- Collaboration agreements with leading research institutions.
What Does RNUGF Do?
Founded in 1997 and headquartered in Pencoed, United Kingdom, ReNeuron Group plc is a biotechnology company dedicated to the research, development, and commercialization of cell-based therapies. The company's primary focus is on addressing significant unmet medical needs through innovative regenerative medicine solutions. ReNeuron's lead product candidate is the CTX stem cell therapy, which is being developed for the treatment of stroke disability. This therapy aims to restore neurological function in stroke patients by replacing damaged brain cells with healthy, functional cells. Another key program is the human retinal progenitor cell (hRPC) therapy, currently in Phase 2 clinical trials, targeting retinitis pigmentosa, a genetic eye disease that leads to progressive vision loss and blindness. The company is also exploring the potential of CTX-derived exosomes, nano-sized vesicles secreted by stem cells, in pre-clinical studies. These exosomes hold promise for various therapeutic applications due to their ability to deliver therapeutic molecules to target cells. In addition to its core therapeutic programs, ReNeuron licenses its ReNcell products, providing research tools for cell biology and neuroscience. ReNeuron has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies, expanding its focus into oncology.
What Products and Services Does RNUGF Offer?
- Researches and develops cell-based therapies.
- Focuses on treatments for stroke disability using CTX stem cell therapy.
- Develops human retinal progenitor cell therapy for retinitis pigmentosa.
- Explores CTX-derived exosomes for various therapeutic applications.
- Licenses ReNcell products for research purposes.
- Collaborates with University College London on anti-cancer cell therapies.
How Does RNUGF Make Money?
- Develops and patents cell-based therapies.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval for commercialization.
- Licenses ReNcell products to generate revenue.
- Forms collaborations and partnerships for research and development.
What Industry Does RNUGF Operate In?
ReNeuron Group plc operates within the rapidly evolving biotechnology industry, specifically in the regenerative medicine and cell therapy space. This sector is characterized by high growth potential, driven by aging populations and increasing demand for innovative treatments for chronic and debilitating diseases. The competitive landscape includes established pharmaceutical companies, as well as smaller biotech firms focused on cell and gene therapies. ReNeuron's focus on stroke disability and retinitis pigmentosa positions it within niche markets with significant unmet needs. The industry is subject to stringent regulatory oversight, with companies required to navigate complex clinical trial processes and regulatory approval pathways.
Who Are RNUGF's Key Customers?
- Patients with stroke disability.
- Patients with retinitis pigmentosa.
- Researchers in cell biology and neuroscience.
- Pharmaceutical companies seeking partnerships.
- Academic institutions involved in research collaborations.
Company Profile
ReNeuron Group plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Pencoed, GB. The company is led by CEO Iain Gladstone Ross. RNUGF has traded publicly since 2007.
Financial Health
ReNeuron Group plc's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -38.75 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for ReNeuron Group plc stands at -72.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -56.1%, showing how much profit it generates from its asset base. A current ratio of 2.05 indicates the company holds enough short-term assets to cover its near-term obligations.
RNUGF Valuation & Market Position
Relative to its peer group, RNUGF's quantitative score of 57/100 is below the peer average of 73/100.
Earnings Track Record
ReNeuron Group plc has beaten Wall Street's EPS estimate in 4 of its last 4 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 28.1% above estimates on average.
RNUGF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary cell-based therapy technologies.
- Focus on unmet medical needs.
- Collaboration with University College London.
- Pipeline of product candidates in various stages of development.
Bear Case
- Negative ROE and free cash flow.
- Reliance on the OTC market.
- Limited financial resources.
- High risk of clinical trial failure.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
RNUGF Latest News
No recent news available for RNUGF.
RNUGF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RNUGF.
Price Targets
Wall Street price target analysis for RNUGF.
RNUGF MoonshotScore
What does this score mean?
The MoonshotScore rates RNUGF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
RNUGF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ReNeuron Group plc may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier may have limited financial reporting, making it difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of regulatory oversight and potential for fraud or manipulation. This tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or questionable business practices.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Evaluate the company's stock structure and potential dilution.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Established history since 1997.
- Focus on research and development of cell-based therapies.
- Collaboration agreement with University College London.
- Pipeline of product candidates in clinical trials.
- Presence in the biotechnology sector.
RNUGF Healthcare Stock FAQ
What does the AI Score mean for RNUGF?
RNUGF holds an AI Score of 57/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. ReNeuron Group plc is a UK-based biotechnology company focused on developing cell-based therapies for areas of significant unmet medical need. Their pipeline includes treatments for stroke …
What does ReNeuron Group plc do?
ReNeuron Group plc is a UK-based biotechnology company focused on developing cell-based therapies for debilitating conditions with significant unmet medical needs. Their primary focus is on regenerative medicine, particularly through their CTX stem cell therapy for stroke disability and human retinal progenitor cell therapy for retinitis pigmentosa.
What are the main risks for RNUGF?
Investing in ReNeuron Group plc carries several risks inherent to the biotechnology industry and its OTC listing. Clinical trial failures for their key product candidates, such as the CTX stem cell therapy and the human retinal progenitor cell therapy, could significantly impact the company's value. Regulatory hurdles and potential delays in obtaining product approvals pose another risk.
How does ReNeuron Group plc navigate regulatory approval processes?
As a biotechnology company developing cell-based therapies, ReNeuron Group plc must navigate stringent regulatory approval processes in both the UK and other target markets. This involves conducting rigorous pre-clinical and clinical trials to demonstrate the safety and efficacy of their product candidates.
What are the key factors to evaluate for RNUGF?
ReNeuron Group plc (RNUGF) holds an AI score of 57/100 (moderate). ReNeuron Group plc presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does RNUGF data refresh on this page?
RNUGF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RNUGF's recent stock price performance?
ReNeuron Group plc (RNUGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary cell-based therapy technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RNUGF overvalued or undervalued right now?
ReNeuron Group plc (RNUGF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RNUGF before investing?
Before investing in ReNeuron Group plc (RNUGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or less reliable than exchange-listed stocks.